|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US3710795A
(en)
|
1970-09-29 |
1973-01-16 |
Alza Corp |
Drug-delivery device with stretched, rate-controlling membrane
|
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
DE3374837D1
(en)
|
1982-02-17 |
1988-01-21 |
Ciba Geigy Ag |
Lipids in the aqueous phase
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
EP0143949B1
(en)
|
1983-11-01 |
1988-10-12 |
TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION |
Pharmaceutical composition containing urokinase
|
|
US4808608A
(en)
|
1986-01-23 |
1989-02-28 |
Merck & Co., Inc. |
Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
|
|
US5374426A
(en)
|
1986-09-03 |
1994-12-20 |
University Of Saskatchewan |
Rotavirus nucleocapsid protein VP6 in vaccine compositions
|
|
US4863457A
(en)
|
1986-11-24 |
1989-09-05 |
Lee David A |
Drug delivery device
|
|
US5164188A
(en)
|
1989-11-22 |
1992-11-17 |
Visionex, Inc. |
Biodegradable ocular implants
|
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
|
US5218105A
(en)
|
1990-07-27 |
1993-06-08 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
|
US5138045A
(en)
|
1990-07-27 |
1992-08-11 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
|
KR0185215B1
(ko)
|
1990-11-30 |
1999-05-01 |
요시다 쇼오지 |
서방성 안구삽입용 약제
|
|
EP0563091A1
(en)
|
1990-12-20 |
1993-10-06 |
SMITHKLINE BEECHAM BIOLOGICALS s.a. |
Vaccines based on hepatitis b surface antigen
|
|
US6565841B1
(en)
|
1991-03-15 |
2003-05-20 |
Amgen, Inc. |
Pulmonary administration of granulocyte colony stimulating factor
|
|
WO1993015722A1
(en)
|
1992-02-07 |
1993-08-19 |
Syntex (Usa) Inc. |
Controlled delivery of pharmaceuticals from preformed porous microparticles
|
|
FR2693813B1
(fr)
|
1992-07-20 |
1994-08-19 |
Commissariat Energie Atomique |
Procédé de réalisation d'une image de référence synthétisée à partir de données contenues dans une base de données CAO.
|
|
FR2705099B1
(fr)
|
1993-05-12 |
1995-08-04 |
Centre Nat Rech Scient |
Oligonucléotides phosphorothioates triesters et procédé de préparation.
|
|
WO1996030523A2
(en)
|
1995-03-31 |
1996-10-03 |
Hans Wolf |
Antigen presentation system based on retrovirus-like particles
|
|
GB9621091D0
(en)
|
1996-10-09 |
1996-11-27 |
Fondation Pour Le Perfectionem |
Attenuated microorganisms strains and their uses
|
|
WO1998016862A1
(fr)
|
1996-10-14 |
1998-04-23 |
Seiko Epson Corporation |
Procede pour la production de verres a foyer progressif
|
|
ATE314095T1
(de)
|
1998-10-21 |
2006-01-15 |
Us Health |
Virusähnliche partikel zur induktion von autoantikörpern
|
|
NZ512456A
(en)
|
1998-11-30 |
2003-10-31 |
Cytos Biotechnology Ag |
Ordered molecular presentation of antigens
|
|
MXPA02009895A
(es)
|
2000-04-07 |
2004-09-06 |
Univ Leeds Innovations Ltd |
Proteinas de fusion de antigeno de nucleo de hepatitis b.
|
|
CA2407897A1
(en)
|
2000-05-05 |
2001-11-15 |
Cytos Biotechnology Ag |
Molecular antigen arrays and vaccines
|
|
ATE320493T1
(de)
|
2000-06-22 |
2006-04-15 |
Ucb Pharma Ltd |
Modifizierung des hepatitis b kernantigens
|
|
US20030138769A1
(en)
|
2000-08-16 |
2003-07-24 |
Birkett Ashley J. |
Immunogenic HBc chimer particles having enhanced stability
|
|
US7264810B2
(en)
|
2001-01-19 |
2007-09-04 |
Cytos Biotechnology Ag |
Molecular antigen array
|
|
AU2002339224B2
(en)
|
2001-09-14 |
2008-10-09 |
Kuros Us Llc |
Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
|
|
DE10201743C2
(de)
|
2002-01-18 |
2003-12-18 |
Aesculap Ag & Co Kg |
Intramedulläres Osteosyntheseimplantat
|
|
ES2350687T3
(es)
|
2002-07-03 |
2011-01-26 |
Ono Pharmaceutical Co., Ltd. |
Composiciones de inmunopotenciación.
|
|
EP2351770A1
(en)
|
2002-07-17 |
2011-08-03 |
Cytos Biotechnology AG |
Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
|
|
SI1524994T1
(sl)
|
2002-07-19 |
2011-08-31 |
Cytos Biotechnology Ag |
Sestavki cepiv, ki vsebujejo amiloidne beta 1-6 antigenske mreĹľe
|
|
DE60319940T2
(de)
|
2002-12-10 |
2008-06-26 |
Haldor Topsoe A/S |
Verfahren zur katalytischen Dehydrierung und Katalysator dafür
|
|
EP1605972A2
(en)
|
2003-03-26 |
2005-12-21 |
Cytos Biotechnology AG |
Hiv-peptide-carrier-conjugates
|
|
US8685435B2
(en)
|
2004-04-30 |
2014-04-01 |
Allergan, Inc. |
Extended release biodegradable ocular implants
|
|
EP1819365B1
(en)
|
2004-12-09 |
2014-07-02 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs
|
|
RU2494107C2
(ru)
|
2005-05-09 |
2013-09-27 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
|
EP1885847B1
(en)
|
2005-05-26 |
2011-07-06 |
Cytos Biotechnology AG |
Scalable fermentation process
|
|
EP1736538A1
(en)
|
2005-06-21 |
2006-12-27 |
Cytos Biotechnology AG |
Process for the preparative purification of virus-like-particles (VLPs)
|
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
EP3342415B1
(en)
|
2006-08-08 |
2022-01-26 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Structure and use of 5' phosphate oligonucleotides
|
|
HRP20131167T1
(hr)
|
2007-06-18 |
2014-01-03 |
Merck Sharp & Dohme B.V. |
Antitijela za humani receptor programirane smrti pd-1
|
|
EP2176408B9
(en)
|
2008-01-31 |
2015-11-11 |
Curevac GmbH |
NUCLEIC ACIDS COMPRISING FORMULA (NuGiXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
|
|
EP2297323A1
(en)
|
2008-05-21 |
2011-03-23 |
Hartmann, Gunther |
5' triphosphate oligonucleotide with blunt end and uses thereof
|
|
US20110184045A1
(en)
|
2008-06-30 |
2011-07-28 |
Gunther Hartmann |
Silencng and rig-i activation by dual function oligonucleotides
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
WO2010028079A2
(en)
|
2008-09-02 |
2010-03-11 |
Alnylam Pharmaceuticals, Inc |
Synthetic methods and derivatives of triphosphate oligonucleotides
|
|
AU2009333580B2
(en)
|
2008-12-09 |
2016-07-07 |
Genentech, Inc. |
Anti-PD-L1 antibodies and their use to enhance T-cell function
|
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
|
RU2013120302A
(ru)
|
2010-10-01 |
2014-11-20 |
Модерна Терапьютикс, Инк. |
Сконструированные нуклеиновые кислоты и способы их применения
|
|
EP2508530A1
(en)
|
2011-03-28 |
2012-10-10 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Purification of triphosphorylated oligonucleotides using capture tags
|
|
RU2648950C2
(ru)
|
2011-10-03 |
2018-04-02 |
Модерна Терапьютикс, Инк. |
Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
|
|
JP2014532400A
(ja)
|
2011-10-31 |
2014-12-08 |
リボックス・ゲーエムベーハー |
免疫賦活用の二本鎖ｒｎａ
|
|
HRP20201595T1
(hr)
|
2011-11-28 |
2020-12-11 |
Merck Patent Gmbh |
Anti-pd-l1 protutijela i njihova uporaba
|
|
WO2013097965A1
(en)
|
2011-12-30 |
2013-07-04 |
Riboxx Gmbh |
Triphosphate-containing double-stranded rna for immunostimulation
|
|
CN113967253A
(zh)
|
2012-05-15 |
2022-01-25 |
百时美施贵宝公司 |
通过破坏pd-1/pd-l1信号传输的免疫治疗
|
|
WO2013180295A1
(ja)
|
2012-06-01 |
2013-12-05 |
日本電信電話株式会社 |
パケット転送処理方法およびパケット転送処理装置
|
|
EP2712870A1
(en)
|
2012-09-27 |
2014-04-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Novel RIG-I ligands and methods for producing them
|
|
WO2014093924A1
(en)
|
2012-12-13 |
2014-06-19 |
Moderna Therapeutics, Inc. |
Modified nucleic acid molecules and uses thereof
|
|
WO2014081507A1
(en)
|
2012-11-26 |
2014-05-30 |
Moderna Therapeutics, Inc. |
Terminally modified rna
|
|
WO2014124433A1
(en)
|
2013-02-11 |
2014-08-14 |
Oregon Health & Science University |
5'-triphosphate oligoribonucleotides
|
|
US20160022840A1
(en)
|
2013-03-09 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Heterologous untranslated regions for mrna
|
|
EP2968391A1
(en)
|
2013-03-13 |
2016-01-20 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
|
US10947543B2
(en)
*
|
2013-03-13 |
2021-03-16 |
Yale University |
Interferon production using short RNA duplexes
|
|
WO2014169049A1
(en)
*
|
2013-04-09 |
2014-10-16 |
Duke University |
2' fluoro-modified rnas as immunostimulators
|
|
US9775894B2
(en)
|
2013-07-09 |
2017-10-03 |
University Of Washington Through Its Center For Commercialization |
Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling
|
|
WO2015038746A1
(en)
|
2013-09-11 |
2015-03-19 |
Georgia Tech Research Corporation |
Compositions and methods for inhibiting gene expression
|
|
WO2015091578A1
(en)
|
2013-12-16 |
2015-06-25 |
Riboxx Gmbh |
Double-stranded polyc:poly(g/i) rna for immunostimulation and cancer treatment
|
|
EP3126501A1
(en)
|
2014-03-24 |
2017-02-08 |
RiboxX GmbH |
Double-stranded rna conjugates and their use
|
|
US9300829B2
(en)
|
2014-04-04 |
2016-03-29 |
Canon Kabushiki Kaisha |
Image reading apparatus and correction method thereof
|
|
WO2016010659A1
(en)
|
2014-07-15 |
2016-01-21 |
Drifire, Llc |
Lightweight, dual hazard fabrics
|
|
US9790509B2
(en)
*
|
2014-07-18 |
2017-10-17 |
Oregon Health & Science University |
5′-triphosphate oligoribonucleotides
|
|
EP3916017A1
(en)
|
2014-12-22 |
2021-12-01 |
PD-1 Acquisition Group, LLC |
Anti-pd-1 antibodies
|
|
WO2017121494A1
(en)
|
2016-01-15 |
2017-07-20 |
Riboxx Gmbh |
5'-triphosphated short immunostimulatory nucleotides, oligonucleotides and polynucleotides
|
|
WO2017173427A1
(en)
*
|
2016-04-01 |
2017-10-05 |
Vycellix Inc |
Novel rna construct and methods of use thereof for enhancing the therapeutic effects of cytotoxic cells and stem cells
|
|
JP2019514939A
(ja)
|
2016-04-26 |
2019-06-06 |
クー バイオロジックス インコーポレイテッドＱｕ Ｂｉｏｌｏｇｉｃｓ Ｉｎｃ． |
標的組織における自然免疫応答の治療的誘発
|
|
US11020473B2
(en)
|
2016-06-24 |
2021-06-01 |
Institut Pasteur |
Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases
|
|
US11382966B2
(en)
*
|
2017-03-24 |
2022-07-12 |
Rigontec Gmbh |
Method for designing RIG-I ligands
|
|
US10736957B2
(en)
*
|
2017-12-19 |
2020-08-11 |
President And Fellows Of Harvard College |
Enhanced immunogenicity of mRNA with co-encoded adjuvant sequences
|
|
EP3727146A4
(en)
*
|
2017-12-19 |
2021-10-06 |
Blaze Bioscience, Inc. |
TUMOR HOMING AND CELL-PENETANT PEPTIDE IMMUNO-ONCOLOGY AGENT COMPLEX AND METHOD OF USE
|
|
KR102890791B1
(ko)
|
2018-04-09 |
2025-11-24 |
체크메이트 파마슈티칼스, 인크. |
바이러스-유사 입자 내로의 올리고뉴클레오타이드의 포장
|
|
WO2019204743A1
(en)
|
2018-04-19 |
2019-10-24 |
Checkmate Pharmaceuticals, Inc. |
Synthetic rig-i-like receptor agonists
|
|
US11516118B2
(en)
|
2018-05-08 |
2022-11-29 |
Telefonaktiebolaget Lm Ericsson (Publ) |
Methods and nodes for enabling management of traffic
|
|
CA3110102A1
(en)
*
|
2018-06-20 |
2019-12-26 |
Yale University |
Rig-i agonists and treatments using same
|
|
EP4048795A1
(en)
|
2019-10-23 |
2022-08-31 |
Checkmate Pharmaceuticals, Inc. |
Synthetic rig-i-like receptor agonists
|
|
CN115376873A
(zh)
|
2021-05-18 |
2022-11-22 |
江苏鲁汶仪器有限公司 |
离子源装置及其使用方法和真空处理系统
|